It is also due to start a phase ... antitrust regulators. Otezla is currently approved only for moderate-to-severe psoriasis, although Amgen has ongoing trials in milder forms of the disease ...

Celgene’s oral psoriasis drug, Otezla (apremilast) looks set to become a blockbuster as sales leapt in Q2. Sales of Otezla were $242 million in Q2, a 170% increase compared with the ...